drugset

drugset / Trial / NCT07384013

Study Protocol: Impact of Metamizole (Optalgin®) on Anti-Xa Concentrations in Oncology Patients Receiving DOACs

NCT07384013 ↗

Recruiting 30 enrolled Rambam Health Care Campus

Non-randomizedParallel-groupOpen-labelOther

Summary

Evaluation of the Effect of metamizole (Optalgin®) on Anti-Xa Levels in Oncology Patients Receiving Direct Oral Anticoagulants (DOACs)

Timeline

Start: 2025-11-01
Primary completion: 2027-12-31
Completion: 2027-12-31

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Metamizole	Unknown	—	—

Indications